XML 17 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Series B Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024   5 85,215    
Beginning balance at Dec. 31, 2024 $ 50,119 $ 0 $ 85 $ 174,779 $ (124,745)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock based compensation 1,599     1,599  
Exercise of warrants (in shares)     50    
Exercise of stock options (in shares)     489    
Exercise of stock options 316   $ 1 315  
Retirement of common shares (in shares)     (106)    
Net loss (23,123)       (23,123)
Ending balance (in shares) at Mar. 31, 2025   5 85,648    
Ending balance at Mar. 31, 2025 28,911 $ 0 $ 86 176,693 (147,868)
Beginning balance (in shares) at Dec. 31, 2025   5 120,070    
Beginning balance at Dec. 31, 2025 245,832 $ 0 $ 120 442,532 (196,820)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock based compensation 4,817     4,817  
Vesting of restricted stock units (in shares)     81    
Vesting of restricted stock units $ (270)     (270)  
Exercise of warrants (in shares) 372   372    
Exercise of warrants $ 2,783   $ 1 2,782  
Exercise of stock options (in shares) 362   362    
Exercise of stock options $ 269     269  
Conversion of convertible notes into common stock (in shares) 420   420    
Conversion of convertible notes into common stock $ 5,059     5,059  
Acquisition of Apium (in shares) 536   536    
Acquisition of Apium $ 6,802   $ 1 6,801  
Net loss (26,553)       (26,553)
Ending balance (in shares) at Mar. 31, 2026   5 121,841    
Ending balance at Mar. 31, 2026 $ 238,739 $ 0 $ 122 $ 461,990 $ (223,373)